UBS Maintains Buy on Biogen, Raises Price Target to $270

UBS analyst Michael Yee has reiterated a Buy rating on Biogen (NASDAQ: BIIB) and increased the price target from $240 to $270. This adjustment reflects a positive outlook on the company's performance.